Association of AGTR1 gene A1166C polymorphism with the risk of heart failure: a meta-analysis

Ja, Zhang; Li, Qing; Yj, Qiao

doi:10.4238/2015.august.7.26

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a hepatic manifestation of the metabolic syndrome, we can suppose that NAFLD may promote the development of atherosclerosis [ 5 , 6 ]. Some reports demonstrated that because of the promoting effect on CVD, NAFLD patients were at high risk of death [ 8 , 10 ]. Nowadays many epidemiological and clinical studies focus on the association between NAFLD and CAD [ 19 – 24 ].…”

Section: Discussionmentioning

confidence: 99%

AGTR1 rs3772622 gene polymorphism increase the risk of nonalcoholic fatty liver disease patients suffer coronary artery disease in Northern Chinese Han population

Liu

Lu²,

Yuan

et al. 2016

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundCardiovascular disease (CAD) responsible and nonalcoholic fatty liver disease (NAFLD) are both metabolic diseases, and they are mostly influenced by genetic factors. The aim of our study is to evaluate the relationship between angiotensin II type-1 receptor (AGTR1) gene rs3772622 polymorphisms and the risk of developing coronary artery disease (CAD) in Chinese patients with NAFLD.MethodsGenotype for AGTR1 rs3772622 in 574 NAFLD patients with CAD or 589 NAFLD patients without CAD, 332 CAD patients exclude NAFLD and 338 health control subjects were determined by sequencing and polymerase chain reaction analysis. Relevant statistical methods were employed to analyze the genotypes, alleles and the clinical date. Inter-group differences and associations were assessed statistically using t-tests and Chi square and logistic analyses. The relative risk of AGTR1 rs3772622 for NAFLD was estimated by logistic regression analysis.ResultsNo significant difference in genotype and allele frequency of AGTR1 rs3772622 was found between the NAFLD without CAD population and the controls (P > 0.05). However, makeable difference was found when compared the CAD in patients with NAFLD and CAD free NAFLD patients (P < 0.001 OR = 2.09). Similarly, significant difference was found in AGTR1 rs3772622 genotype distribution between the groups of CAD patients and control (P = 0.046 OR = 1.71).ConclusionsAGTR1 rs3772622 gene polymorphism was not associated with the risk of NAFLD, but could increase the risk of NAFLD patients suffering from CAD in the Chinese Han population. Deeply mechanisms underlying the association between AGTR1 rs3772622 gene polymorphism and the risk of CAD in NAFLD patients need more research.

show abstract

Section: Discussionmentioning

confidence: 99%

AGTR1 rs3772622 gene polymorphism increase the risk of nonalcoholic fatty liver disease patients suffer coronary artery disease in Northern Chinese Han population

Liu

Lu²,

Yuan

et al. 2016

Lipids Health Dis

View full text Add to dashboard Cite

show abstract

Pharmacogenomics of Heart Failure: a Systematic Review

2016

View full text Add to dashboard Cite

show abstract

Some Genetic Risk Markers for Postinfarction Heart Failure

Lozhkina

Mukaramov

Максимов

2023

Mediko-farmacevtičeskij žurnal "Pulʹs"

View full text Add to dashboard Cite

Вackground. Postinfarction heart failure is a serious complication of myocardial infarction requiring personalized early diagnosis, and in particular, using molecular genetic markers. Purpose of the study. To determine the role of different genotype variants according to polymorphic variants: rs5186 of angiotensin II receptor A1166 C type 1 gene and rs5068 of atrial natriuretic peptide gene in the development of chronic heart failure in postinfarction period. Patient Characterization and Research Methods. An open prospective non-randomized cohort study by parallel-group method included 186 patients (mean age 63.5 years) who underwent myocardial infarction from January 2019 to January 2020 and were treated at the regional vascular center No 1 of City Clinical Hospital No 1 of Novosibirsk. Novosibirsk. The study group consisted of 86 people with signs of CHF above the 2nd class (NYHA) and the comparison group consisted of 100 people without signs of CHF or with CHF of the 1st class (NYHA). The diagnosis of MI and CHF was made according to national and European guidelines [1, 2]. Both groups received standard therapy for these pathologies. Clinical outcomes were assessed 1 year after discharge: cardiovascular mortality, repeated hospitalizations due to CHF decompensation, death from other causes, stroke, recurrent myocardial infarction, unscheduled coronary revascularization. Methods of statistical analysis. Statistical analysis was performed with the help of SPSS 22.0 program modules. Results. There were no statistically significant differences in the frequencies of rs5186 genotypes and alleles of AGTR1 gene between the main group with CHF and the comparison group. Carriage of genotype with the G allele of rs5068 of the NPPA gene was 5.1 times higher in the group with CHF compared with the comparison group by odds ratio (GA + GG vs AA, 95% CI 1.64-16.16; p = 0.003). In women, carriage of the GG and GA genotypes was also associated with an increased odds ratio (OR) of having CHF compared with the AA genotype, OR 5.98 (95% CI 1.24-28.83; p = 0.028). Conclusion: carriage of genotype G allele rs5068 of NPPA gene increases risk of postinfarct chronic heart failure by 5.1 times; rs5186 of AGTR1 gene has no effect on this complication of MI.

show abstract

Association of AGTR1 gene A1166C polymorphism with the risk of heart failure: a meta-analysis

Cited by 3 publications

References 26 publications

AGTR1 rs3772622 gene polymorphism increase the risk of nonalcoholic fatty liver disease patients suffer coronary artery disease in Northern Chinese Han population

AGTR1 rs3772622 gene polymorphism increase the risk of nonalcoholic fatty liver disease patients suffer coronary artery disease in Northern Chinese Han population

Pharmacogenomics of Heart Failure: a Systematic Review

Some Genetic Risk Markers for Postinfarction Heart Failure

Contact Info

Product

Resources

About